Cambridge Cognition Holdings PLC represents a commitment to scientific excellence and innovation in cognitive research. With a focus on developing cutting-edge technology and software solutions, the company aims to transform the understanding and treatment of brain-related disorders. Cambridge Cognition places great emphasis on collaboration and partnerships with renowned academic institutions and pharmaceutical companies, allowing the company to remain at the forefront of cognitive science. With a dedication to improving patient outcomes, Cambridge Cognition strives to provide accurate and reliable assessments for clinical trials and patient care. By continuously pushing the boundaries of cognitive assessment, this company is leading the way in advancing neuroscience research.

Cambridge Cognition Holdings PLC is primarily present in the United Kingdom.

Cambridge Cognition Holdings PLC, a leading cognitive neuroscience company, has achieved significant milestones in its journey. The company has successfully developed and launched innovative digital health technologies and cognitive assessment solutions. It has collaborated with renowned research institutions and pharmaceutical companies, forging strong partnerships to advance scientific knowledge and drive clinical research. Cambridge Cognition Holdings PLC has also expanded its global reach, effectively penetrating new markets and establishing a solid presence across the globe. Through continuous innovation and dedication, the company has positioned itself as a trusted leader in the field, empowering researchers and clinicians to make informed decisions for better patient outcomes.

Cambridge Cognition Holdings PLC, a leading neuroscience technology company, has a rich history and background. Founded in 1999, the company focuses on developing cutting-edge digital health solutions. It began as a spin-out from the University of Cambridge, leveraging the world-class research and expertise of the university. Cambridge Cognition Holdings PLC has since established itself as a global leader in cognitive assessment and monitoring. Its innovative software tools and digital health technologies, backed by extensive research, enable the assessment of cognitive health and the early detection of neurological disorders. With a strong emphasis on scientific rigor and rigorous standards, Cambridge Cognition Holdings PLC continues to revolutionize cognitive healthcare.

Cambridge Cognition Holdings PLC faces competition from several key players in the market. Some of its main competitors include Cogstate Ltd, which offers cognitive assessment tools and services; ProPhase Labs Inc, known for their innovative cognitive health products; and Brain Resource Company Pty Ltd, a company that specializes in online brain health assessments and training. These competitors strive to offer similar services and solutions, creating a competitive landscape for Cambridge Cognition Holdings PLC.

Cambridge Cognition Holdings PLC is primarily active in the healthcare and pharmaceutical industries.

The business model of Cambridge Cognition Holdings PLC is focused on providing digital solutions in cognitive health, clinical trials, and neuroscience research. The company offers software tools and services that enable the assessment of cognitive function and mental health. Cambridge Cognition's technology is used by pharmaceutical companies, research institutions, and healthcare providers to improve the understanding and treatment of neurological and psychiatric disorders. With their innovative solutions and expertise in cognition, the company aims to help customers in accelerating drug development, advancing scientific research, and ultimately improving patient outcomes. Cambridge Cognition Holdings PLC is committed to delivering cutting-edge solutions in the field of cognitive health.

De Cambridge Cognition Holdings K/W is 0.

De Cambridge Cognition Holdings KUV is 1,03.

De AlleAktien Kwaliteitsscore voor Cambridge Cognition Holdings is 4/10.

De verwachte Cambridge Cognition Holdings omzet is 14,42 mln. GBP.

De winst kan momenteel niet berekend worden voor Cambridge Cognition Holdings.

Cambridge Cognition Holdings PLC is a leading company in the field of digital cognitive health research. The company's business model is based on the development and provision of software products to support clinical studies and research projects in the field of cognitive health. The company offers various digital tools that help measure and improve patients' cognitive health. The focus is on researching diseases such as Alzheimer's, schizophrenia, depression, and anxiety disorders. The tools include mobile applications, web applications, and software solutions that can run on tablets and other digital devices. Cambridge Cognition Holdings PLC distributes its tools and services to research institutes as well as companies in the pharmaceutical and biotech industries. The company works closely with its customers to develop and offer customized solutions. The latest scientific knowledge is used, and the needs and requirements of customers are taken into account when developing new products. Another important aspect of Cambridge Cognition Holdings PLC's business model is the acquisition of research projects. The company uses its own products and expertise to conduct clinical studies in the field of cognitive health. The data from these studies can then be used by the company's customers to develop new drugs and therapies. A central aspect of Cambridge Cognition Holdings PLC's business model is innovation. The company is constantly striving to further develop its products and services and offer new solutions in the field of digital cognitive health research. To this end, the company continuously invests in research and development and works closely with leading scientists in this field. Cambridge Cognition Holdings PLC aims to play a leading role in digital cognitive health research. The company relies on open and transparent collaboration with its customers and partners. By pooling resources and expertise, innovative solutions in the field of cognitive health are to be developed, which provide real added value for patients and society as a whole. Overall, Cambridge Cognition Holdings PLC's business model is focused on continuous growth and success. By developing and improving tools and services in the field of digital cognitive health research, the company aims to accelerate research and improve disease treatment.

Cambridge Cognition Holdings keert een dividend van 0 GBP uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Cambridge Cognition Holdings of het bedrijf keert geen dividend uit.

De ISIN van Cambridge Cognition Holdings is GB00B8DV9647.

Het WKN van Cambridge Cognition Holdings is A1T9LW.

De ticker van Cambridge Cognition Holdings is COG.L.

Binnen de laatste 12 maanden betaalde Cambridge Cognition Holdings een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Cambridge Cognition Holdings naar verwachting een dividend van 0 GBP betalen.

De dividendrendement van Cambridge Cognition Holdings is momenteel .

Cambridge Cognition Holdings betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Cambridge Cognition Holdings betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 GBP verwacht. Dit komt overeen met een dividendrendement van 0 %.

Cambridge Cognition Holdings wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Cambridge Cognition Holdings van 18-7-2024 ter hoogte van 0 GBP te ontvangen, moest je het aandeel voor de ex-datum op 18-7-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 18-7-2024.

In het jaar 2023 heeft Cambridge Cognition Holdings 0 GBP aan dividenden uitgekeerd.

De dividenden van Cambridge Cognition Holdings worden in GBP uitgekeerd.